OPT - רווח לפני ריבית, מסים ופחת Opthea

Opthea Limited (OPT) is competing for market share in macular degeneration using FDA-patented combination molecules. The operating benefit trend illustrated by this chart via the GURU.Markets platform shows that the current level is . The business currently relies on external investments without existing cash flows while developing a unique drug to block VEGF-C and D proteins.

This indicator measures net cash inflow from core operations before deducting financial expenses and tax liabilities, reflecting the business's actual ability to convert operational processes into liquidity. An analysis of operating cash flow before interest and taxes for Opthea Limited (OPT) confirms the absence of commercial products, as the development of late-stage trial drugs depends entirely on external financing.